Sparx Biopharmaceutical Corp Revenue

About Sparx Biopharmaceutical Corp

SparX Biopharmaceutical Corp. is a research-based development-stage biopharmaceutical company, dedicated to the mission of “strengthening human immunity using robust antibody therapies” through the discovery and development of innovative immuno-oncology agents. Equipped with big data analytical techniques, such as machine learning algorithms, SparX extracts potential interactions from large volumes of complex multi-dimensional public information. Mechanistic pharmacological analyses coupled with in vitro and in vivo evaluations using the syngeneic, transgenic and humanized mouse models, enables SparX’s focus on developing novel or best-in-class therapeutics demonstrating substantial advantages over existing therapies. Target discovery and validation has historically been the bottleneck in drug development. SparX combines its sophisticated target discovery platform with an integrated multi-component SAILING™ antibody optimization system and a cutting-edge bi-ADC technology to markedly improve the success rate of empowered antibody drug development. In addition to the integrated antibody discovery platform, SparX has built in-house cGMP facilities of significant capacity to produce clinical and commercial drug products, facilitating its evolution into an integrated and independent biopharmaceutical company.

View contact profiles from Sparx Biopharmaceutical Corp